Paratek Pharmaceuticals, Inc. (PRTK): Price and Financial Metrics

Paratek Pharmaceuticals, Inc. (PRTK): $1.83

0.09 (+4.89%)

POWR Rating

Component Grades













Add PRTK to Watchlist
Sign Up

Industry: Biotech



in industry


  • PRTK scores best on the Value dimension, with a Value rank ahead of 79.11% of US stocks.
  • The strongest trend for PRTK is in Stability, which has been heading up over the past 179 days.
  • PRTK's current lowest rank is in the Momentum metric (where it is better than 4.64% of US stocks).

PRTK Stock Summary

  • The capital turnover (annual revenue relative to shareholder's equity) for PRTK is -1.02 -- better than merely 4.13% of US stocks.
  • PRTK's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of only 4.46% of US stocks.
  • Revenue growth over the past 12 months for Paratek Pharmaceuticals Inc comes in at 177.39%, a number that bests 95.37% of the US stocks we're tracking.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Paratek Pharmaceuticals Inc are OSIS, QUOT, HRMY, ISR, and REKR.
  • Visit PRTK's SEC page to see the company's official filings. To visit the company's web site, go to

PRTK Valuation Summary

  • PRTK's EV/EBIT ratio is -12.7; this is 143.34% lower than that of the median Healthcare stock.
  • Over the past 153 months, PRTK's price/sales ratio has gone up 2.3.
  • PRTK's EV/EBIT ratio has moved down 13.1 over the prior 153 months.

Below are key valuation metrics over time for PRTK.

Stock Date P/S P/B P/E EV/EBIT
PRTK 2021-08-31 2.6 -2.7 -5.0 -12.7
PRTK 2021-08-30 2.6 -2.7 -5.0 -12.7
PRTK 2021-08-27 2.6 -2.7 -5.0 -12.7
PRTK 2021-08-26 2.5 -2.6 -4.8 -12.5
PRTK 2021-08-25 2.6 -2.7 -4.9 -12.6
PRTK 2021-08-24 2.6 -2.7 -4.9 -12.6

PRTK Growth Metrics

    The year over year net income to common stockholders growth rate now stands at 27.75%.
  • The 2 year price growth rate now stands at -58.75%.
  • The 2 year net cashflow from operations growth rate now stands at -76.91%.
Over the past 15 months, PRTK's revenue has gone up $90,290,000.

The table below shows PRTK's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-12-31 130.162 -48.273 -59.084
2021-09-30 114.387 -52.315 -51.841
2021-06-30 103.599 -107.493 -54.494
2021-03-31 55.433 -94.616 -87.27
2020-12-31 46.924 -103.424 -96.541
2020-09-30 39.872 -115.104 -98.896

PRTK's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • PRTK has a Quality Grade of D, ranking ahead of 16.58% of graded US stocks.
  • PRTK's asset turnover comes in at 0.58 -- ranking 64th of 680 Pharmaceutical Products stocks.
  • BHVN, EVFM, and IBRX are the stocks whose asset turnover ratios are most correlated with PRTK.

The table below shows PRTK's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.580 0.831 -0.114
2021-03-31 0.291 0.821 -0.222
2020-12-31 0.224 0.816 -0.242
2020-09-30 0.175 0.812 -0.234
2020-06-30 0.125 0.787 -0.259
2020-03-31 0.090 0.792 -0.276

PRTK Price Target

For more insight on analysts targets of PRTK, see our PRTK price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $21.75 Average Broker Recommendation 1.25 (Strong Buy)

PRTK Stock Price Chart Interactive Chart >

Price chart for PRTK

PRTK Price/Volume Stats

Current price $1.83 52-week high $11.24
Prev. close $1.74 52-week low $1.68
Day low $1.69 Volume 191,475
Day high $1.84 Avg. volume 463,205
50-day MA $2.45 Dividend yield N/A
200-day MA $4.03 Market Cap 99.42M

Paratek Pharmaceuticals, Inc. (PRTK) Company Bio

Paratek Pharmaceuticals focuses on the development and commercialization of antibacterial therapeutics based upon tetracycline chemistry in the United States. The company was founded in 1996 and is based in in Boston, Massachusetts.

PRTK Latest News Stream

Event/Time News Detail
Loading, please wait...

PRTK Latest Social Stream

Loading social stream, please wait...

View Full PRTK Social Stream

Latest PRTK News From Around the Web

Below are the latest news stories about Paratek Pharmaceuticals Inc that investors may wish to consider to help them evaluate PRTK as an investment opportunity.

What Is The Ownership Structure Like For Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK)?

If you want to know who really controls Paratek Pharmaceuticals, Inc. ( NASDAQ:PRTK ), then you'll have to look at the...

Yahoo | February 8, 2022

Kalos Management, Inc. Buys Vale SA, Sells Consensus Cloud Solutions Inc, Intuitive Surgical ...

Investment company Kalos Management, Inc. (Current Portfolio) buys Vale SA, sells Consensus Cloud Solutions Inc, Intuitive Surgical Inc, Amarin Corp PLC, Catalyst Biosciences Inc, Paratek Pharmaceuticals Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Kalos Management, Inc..

Yahoo | February 3, 2022

AGF Investments LLC Buys Health Care Select Sector SPDR, Financial Select Sector SPDR, The ...

Investment company AGF Investments LLC (Current Portfolio) buys Health Care Select Sector SPDR, Financial Select Sector SPDR, The Energy Select Sector SPDR Fund, Paratek Pharmaceuticals Inc, Hello Group Inc, sells Industrial Select Sector SPDR, Consumer Staples Select Sector SPDR, Utilities Select Sector SPDR ETF, Microsoft Corp, UnitedHealth Group Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, AGF Investments LLC.

Yahoo | February 2, 2022

Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

BOSTON, Feb. 01, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian, government and military use, today announced that on January 31, 2022, the Company granted stock options to six new employees of the Company. These awards were granted pursuant to the Paratek Pharmaceuticals, In

Yahoo | February 1, 2022

Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) General Counsel Sells $21,551.92 in Stock

Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) General Counsel William M. Haskel sold 4,876 shares of the companys stock in a transaction dated Monday, December 13th. The shares were sold at an average price of $4.42, for a total transaction of $21,551.92. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is []

Dakota Financial News | December 18, 2021

Read More 'PRTK' Stories Here

PRTK Price Returns

1-mo -16.82%
3-mo -48.74%
6-mo -58.22%
1-year -77.76%
3-year -56.22%
5-year -90.90%
YTD -59.24%
2021 -28.27%
2020 55.33%
2019 -21.44%
2018 -71.34%
2017 16.23%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.6042 seconds.